High-dose Docetaxel with Granulocyte Colony-stimulating Factor for Mobilization of Autologous Peripheral Blood Stem/Progenitor Cells in Patients with Malignant Solid Tumors

邸立军,任军,余靖,宋国红,张春荣,孟松娘,车利,方健

2008-01-01

Abstract:Objective The efficacy of high-dose therapy(HDT) with peripheral blood progenitor cell(PBPC) transplantation for patients with solid tumors remains undefined.An important prerequisite for this mode of therapy is a reliable methord of obtaining sufficient PBPCs to ensure rapid and durable engraftment while maintaining patients in at least a stable disease state at the time of commencing the high-dose phase of therapy.Docetaxel has an effective anti-tumour activity in mang solid tumors.The objective of our study is to explore the efficacy and safety of high-dose of docetaxel with granulocyte colony-stimulating factor(G-CSF) for mobilization of peripheral blood stem cells.Methods The 30 patients with malignant solid tumors were involved in our study.Docetaxel(120 mg/m2) was given with a continuous intravenous infusion for 3 hours on day 1.When the number of white blood cell was reached to 1.0×109/L,G-CSF 5 μg/kg was given twice a day by injection subcutaneous until the end of leukopheresis.Results The leukopheresis was started on average day 9.97±1.03 following docetaxel therapy,the mean number of CD34+ cells was 3.49×106/kg(range 1.71×106/kg～16.69×106/kg),by two times per patient of leukopheresis.There are 25 cases whose number of CD34+ cells is more than 2.0×106/kg.The average day is(6.47±1.01) when the number of white blood cells was reduced to 1.0×109/L after docetaxel was given.The average duration is(3.50±1.01) days for G-CSF injection subcutaneous.No significant difference in number of CD34+ cells was found in different leukopheresis time.6 cases had mild arthralgia,3 cases had slight diarrhea,1 cases had oropharyngeal mucositis.Conclusion Docetaxel(120 mg/m2) with G-CSF(5 μg/kg) is an effective and safety mobilizing regimen for autologous peripheral blood stem progenitor cells in patients with malignant solid tumors.